Allergan Asks to Exit PTAB Review of Restasis Patents

Allergan asked the Patent Trial and Appeal Board to remove it from several patent challenges involving its dry-eye drug Restasis.

The drugmaker transferred its patents for Restasis to the St. Regis Mohawk Native American tribe last year. As a result, the company said, it no longer has the authority to handle the case.

Members of Congress have called for an investigation into the controversial deal and several companies and entities have sued the drugmaker for anticompetitive practices.